Teladoc Health (NYSE: TDOC) announced its 2022 Q1 financial results on April 27, 2022. According to the announcement, total revenue was 565 million USD, up 25% (YoY, 3 months). Meanwhile, Teladoc recorded an operating loss of 6.7 billion USD and a net loss of 6.7 billion USD. These losses were primarily driven by non-cash goodwill impairment charge of 6.6 billion USD. On the other hand, Adjusted EBITDA recorded 54 million USD. It was down 4% year-over-year.
Looking at the revenue details, access fee revenue was up 29% and visit fee revenue was up 12%. Access fee revenue seem to be subscription-based revenues, and it accounts for 87% of Teladoc’s total revenue. Strong growth in the access fee revenue may continuously stabilize Teladoc’s financial condition. Currently, Teladoc Health has a very stable financial condition with a current ratio of 394% and a shareholders’ equity ratio of 82%. Thus, the stock price of Teladoc Health may recover as the market stabilizes.
As for the number of users, it is steadily increasing. For example, U.S. Paid Membership was up 5%, U.S. Visit Free Only Access was up 14%, and Unique Chronic Care Members was up 12%.
Accordingly, Watanabe & Brothers’ Investment will continue the investment in Teladoc Health.
Teladoc Health, Inc. (NYSE: TDOC) Stock Chart
Important Notice
- Watanabe & Brothers’ Investment is holding shares of Teladoc Health.
- This report is provided solely for informational purpose and not intended for the purpose of soliciting investment in, or as a recommendation to purchase or sell any specific products.
- Any opinions or statements expressed in this report are based on the author’s personal and subjective views, and are not the official views of the organization to which the author belongs. In addition, although we have done our best efforts in making accurate assessments on the original financial statements, we cannot guarantee any complete accuracy of this report. We do not guarantee either that any future forecasts referred to in this report will certainly be realized. Investment in listed stocks, ETFs, etc. should be carried out under the responsibility of each investor, and even if the investor who read this report suffers a loss due to investment activities, Watanabe & Brothers’ Investment is not responsible for any liability.
- This report was originally prepared in English, and translated into the other languages with plugin utilizing Google Translation API. We hereby notify that the translations are provided only for the sake of reference, and any opinions or statements in this report should be interpreted in original English. We ask any investors reading this report to refer to the original financial statements issued by the company.